Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut

Long-term results showed five-year survival numbers for lung cancer patients that surpassed all others, and Merck's VP of oncology research tells us what he's excited about.

By Michael Gibney • Oct. 3, 2022

How do Biogen-Eisai’s two Alzheimer’s drugs stack up?

Biogen and Eisai's newest Alzheimer's success begs comparison to their past debacle — and bolsters the amyloid theory.

By Michael Gibney • Sept. 30, 2022

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Woman of the Week: Pepper Bio’s Samantha Dale Strasser

The co-founder of Pepper Bio entered the biotech world three years ago with the goal of transforming drug discovery through the emerging discipline of transomics.

By Taren Grom • Sept. 28, 2022

Woman of the Week: Agilent Technologies’ Dr. Katharine Knobil

As the first chief medical officer of the diagnostic testing company, Dr. Katharine Knobil is focused on moving the science forward beyond precision oncology to liquid biopsy.

By Taren Grom • Sept. 14, 2022

From the ‘go-go days’ to a bubble crunch — the biotech sector faces its next challenge

The highs of the sector in early 2021 gave way to a bear market that persisted into the second half of this year — but there's hope the bubble hasn't popped for good.

By Michael Gibney • Sept. 12, 2022

Woman of the Week: Foresite Capital’s Cindy Mesaros

The longtime marketing pro details her fascinating career journey and how she’s positioning early stage health companies to thrive. 

By Taren Grom • Sept. 7, 2022

First 90 Days: Adaptive Biotech’s Tycho Peterson

A long-time analyst, Tycho Peterson brings his business savvy to the C-suite at Adaptive, where he began as CFO in June with a knowledge of what works and what doesn't in the diagnostics space.

By Michael Gibney • Sept. 1, 2022

Woman of the Week: Thread’s Kim Boericke

Fresh off an eight-year tour of duty at ICON, the CRO industry veteran is stepping into a new role and a new title as chief delivery officer at Thread.

By Taren Grom • Aug. 31, 2022

Leading the industry’s next potential game-changer in drug discovery

Rachel Meyers, chief scientific officer at Faze Medicines, is helping guide the company towards the development of biomolecular condensates — an emerging field that could transform drug discovery.

By Alexandra Pecci • Aug. 29, 2022

Woman of the Week: Glympse Bio’s Dr. Tram Tran

How the chief medical officer of the emerging diagnostic company is using the patient perspective as a guiding light.

By Taren Grom • Aug. 24, 2022

Moderna, Eli Lilly and Schrödinger seek to boost financial and people strategies with key new hires

How the latest personnel shifts are impacting each company and the industry at large. 

By Karissa Waddick • Aug. 24, 2022

The story behind the PharmaVoice 100

Taren Grom, our founding editor and the feature’s originator, explains how the coveted PharmaVoice 100 awards got its start and what makes it stand out in the industry.

By Meagan Parrish • Aug. 23, 2022

As pharma M&A ramps up, U.S. execs are bullish on more deals

What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

By Michael Gibney • Aug. 11, 2022

Woman of the Week: COTA’s Miruna Sasu

Miruna Sasu is on a mission to use real world data to help wipe out cancer. She believes this audacious goal is within reach, and as president and CEO of COTA, she is inspiring her team to create a “path to care” for oncology patients.

By Taren Grom • Aug. 10, 2022

Are Big Pharma CEOs earning their pay?

While compensation packages at the top may not always reflect value, it’s not necessarily an industrywide problem.

By Kelly Bilodeau • Aug. 8, 2022

Woman of the Week: Alloy Therapeutics’ Heather Schwoebel

The CBO and COO is leaning on her experience navigating the unknown to turn Alloy into an innovation multiplier.

By Taren Grom • Aug. 3, 2022

Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires

How these latest executive personnel changes are impacting the industry. 

By Karissa Waddick • Aug. 3, 2022

How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond

WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

By Kim Ribbink • Aug. 1, 2022

What’s next for Biogen? Here’s what executives are saying

A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?

By Michael Gibney • July 27, 2022

Woman of the Week: Applied BioMath's Katie Williams

The 2022 president of Women in Bio is equal parts math and gender parity evangelist. 

By Taren Grom • July 27, 2022

With big changes ahead for J&J and Novartis, here's what the companies' execs are talking about

Both J&J and Novartis are making — or considering — big shifts in their fundamental company makeup.

By Michael Gibney • July 21, 2022

Making moves: Agios, BeiGene, Biocom California and more announce new key hires

The latest executive personnel changes from around the industry.

By Karissa Waddick • July 18, 2022

Digital Opinion Leader deep-dive: the sharer

Learn about Digital Opinion Leaders who curate tailored content experiences and provide value to their followers. 

July 18, 2022

Anjarium Biosciences’ CEO on its next-gen gene therapies

Stephen Yoo aims to build on the buzz around the company’s leading-edge gene therapy tech.

By Kim Ribbink • July 15, 2022

Janssen extends LGBTQ mental health outreach beyond Pride Month

The pharma giant’s ‘Depression looks like me’ campaign assembles a ‘one stop shop’ of resources to help combat high rates of severe depression in the LGBTQ community.

By Karissa Waddick • July 14, 2022